These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Advances in the prevention of Alzheimer's disease and dementia. Solomon A; Mangialasche F; Richard E; Andrieu S; Bennett DA; Breteler M; Fratiglioni L; Hooshmand B; Khachaturian AS; Schneider LS; Skoog I; Kivipelto M J Intern Med; 2014 Mar; 275(3):229-50. PubMed ID: 24605807 [TBL] [Abstract][Full Text] [Related]
24. The world of dementia beyond 2020. Brodaty H; Breteler MM; Dekosky ST; Dorenlot P; Fratiglioni L; Hock C; Kenigsberg PA; Scheltens P; De Strooper B J Am Geriatr Soc; 2011 May; 59(5):923-7. PubMed ID: 21488846 [TBL] [Abstract][Full Text] [Related]
25. Clinical indications for analysis of Alzheimer's disease CSF biomarkers. Engelborghs S Rev Neurol (Paris); 2013 Oct; 169(10):709-14. PubMed ID: 24016466 [TBL] [Abstract][Full Text] [Related]
26. Prospective one-year cost-of-illness study in a cohort of patients with dementia of Alzheimer's disease type in Spain: the ECO study. Coduras A; Rabasa I; Frank A; Bermejo-Pareja F; López-Pousa S; López-Arrieta JM; Del Llano J; León T; Rejas J J Alzheimers Dis; 2010; 19(2):601-15. PubMed ID: 20110605 [TBL] [Abstract][Full Text] [Related]
27. Medical costs of Alzheimer's disease misdiagnosis among US Medicare beneficiaries. Hunter CA; Kirson NY; Desai U; Cummings AK; Faries DE; Birnbaum HG Alzheimers Dement; 2015 Aug; 11(8):887-95. PubMed ID: 26206626 [TBL] [Abstract][Full Text] [Related]
28. Mortality and treatment costs have a great impact on the cost-effectiveness of disease modifying treatment in Alzheimer's disease--a simulation study. Sköldunger A; Johnell K; Winblad B; Wimo A Curr Alzheimer Res; 2013 Feb; 10(2):207-16. PubMed ID: 23036018 [TBL] [Abstract][Full Text] [Related]
29. [Biological markers in the diagnosis of dementia and Alzheimer's disease]. Meiner Z; Rosenmann H Harefuah; 2012 May; 151(5):289-93, 318. PubMed ID: 22844733 [TBL] [Abstract][Full Text] [Related]
30. Alzheimer's disease. AMA Council on Scientific Affairs Reference Committee D. J Okla State Med Assoc; 1998 Aug; 91(5):298-306. PubMed ID: 9714972 [TBL] [Abstract][Full Text] [Related]
31. Relevance of magnetic resonance imaging for early detection and diagnosis of Alzheimer disease. Teipel SJ; Grothe M; Lista S; Toschi N; Garaci FG; Hampel H Med Clin North Am; 2013 May; 97(3):399-424. PubMed ID: 23642578 [TBL] [Abstract][Full Text] [Related]
32. Economic considerations of Alzheimer's disease and related disorders. Michel JP; Zekry D; Mulligan R; Giacobini E; Gold G Aging (Milano); 2001 Jun; 13(3):255-60. PubMed ID: 11442307 [TBL] [Abstract][Full Text] [Related]
33. Design of comprehensive Alzheimer's disease centers to address unmet national needs. Trojanowski JQ; Arnold SE; Karlawish JH; Brunden K; Cary M; Davatzikos C; Detre J; Gaulton G; Grossman M; Hurtig H; Jedrziewski K; McCluskey L; Naylor M; Polsky D; Schellenberg GD; Siderowf A; Shaw LM; Van Deerlin V; Wang LS; Werner R; Xie SX; Lee VM Alzheimers Dement; 2010 Mar; 6(2):150-5. PubMed ID: 20298979 [TBL] [Abstract][Full Text] [Related]
34. Economic evaluation of supplementing the diet with Souvenaid in patients with prodromal Alzheimer's disease. Mar J; Gorostiza A; Ibarrondo O; Larrañaga I; Arrospide A; Martinez-Lage P; Soto-Gordoa M Alzheimers Res Ther; 2020 Dec; 12(1):166. PubMed ID: 33308302 [TBL] [Abstract][Full Text] [Related]
35. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. McKhann GM; Knopman DS; Chertkow H; Hyman BT; Jack CR; Kawas CH; Klunk WE; Koroshetz WJ; Manly JJ; Mayeux R; Mohs RC; Morris JC; Rossor MN; Scheltens P; Carrillo MC; Thies B; Weintraub S; Phelps CH Alzheimers Dement; 2011 May; 7(3):263-9. PubMed ID: 21514250 [TBL] [Abstract][Full Text] [Related]
36. Methods of cost-effectiveness analysis in the assessment of new drugs for Alzheimer's disease. Neumann PJ; Hermann RC; Berenbaum PA; Weinstein MC Psychiatr Serv; 1997 Nov; 48(11):1440-4. PubMed ID: 9355172 [TBL] [Abstract][Full Text] [Related]
37. Pharmacological therapy for people with Alzheimer's disease: the balance of clinical effectiveness, ethical issues and social and healthcare costs. Ballard C; Sorensen S; Sharp S J Alzheimers Dis; 2007 Aug; 12(1):53-9. PubMed ID: 17851194 [TBL] [Abstract][Full Text] [Related]
38. Diagnosis and biomarkers of predementia in Alzheimer's disease. Forlenza OV; Diniz BS; Gattaz WF BMC Med; 2010 Dec; 8():89. PubMed ID: 21176189 [TBL] [Abstract][Full Text] [Related]
39. Using cognitive decline in novel trial designs for primary prevention and early disease-modifying therapy trials of Alzheimer's disease. Darby D; Brodtmann A; Woodward M; Budge M; Maruff P Int Psychogeriatr; 2011 Nov; 23(9):1376-85. PubMed ID: 21477408 [TBL] [Abstract][Full Text] [Related]